AIR-001 first human clinical results
AIRNA says AIR-001 was in the clinic by June 2026. The RNA-editing candidate is designed to repair the disease-driving AATD variant and restore functional alpha-1 antitrypsin.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- The June announcement establishes clinical-stage status, not an unreported future result; check for subsequent disclosures.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Phase 1 readout candidate — date unconfirmed
Company context
Opened 2026 Puma Biotechnology preliminary proxy. Director Allison Dorval biography explicitly identifies AIRNA Corporation as a private biotechnology company. Positive filed-issuer self-report about a director affiliation, not an independent October 31 company-registry audit; exact filing day was not independently extracted.
Potential outcome market
Will AIRNA publicly report human safety and functional-AAT results for AIR-001 by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.